Identification

Name
Dexbrompheniramine
Accession Number
DB00405  (APRD00770)
Type
Small Molecule
Groups
Approved
Description

Dexbrompheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria.

Structure
Thumb
Synonyms
  • (+)-Brompheniraminum
  • (+)-parabromdylamine
  • (R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine
  • (S)-(+)-Brompheniramine
  • (S)-Brompheniramine
  • 3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine
  • D-Brompheniramine
  • Desbrofeniramina
  • Dexbromfeniramina
  • Dexbrompheniramin
  • Dexbromphéniramine
  • Dexbrompheniraminum
  • Parabromodylamine
Product Ingredients
IngredientUNIICASInChI Key
Dexbrompheniramine maleateBPA9UT29BS2391-03-9SRGKFVAASLQVBO-DASCVMRKSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ala-hist IrTablet2 mg/1OralPoly Pharmaceuticals2011-08-22Not applicableUs
PediaVentTablet, chewable1 mg/1OralCarwin Associates, Inc2014-08-05Not applicableUs
PediaVentSyrup2 mg/5mLOralCarwin Associates, Inc2014-08-04Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ActiconDexbrompheniramine maleate (2 mg/1) + Pseudoephedrine hydrochloride (60 mg/1)TabletOralActipharma, Inc2015-08-13Not applicableUs
ActiconDexbrompheniramine maleate (1 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralActipharma, Inc2016-07-14Not applicableUs
ActidogesicDexbrompheniramine maleate (1 mg/1) + Acetaminophen (500 mg/1)TabletOralActipharma, Inc2016-10-14Not applicableUs
Ala-hist PEDexbrompheniramine maleate (2 mg/1) + Phenylephrine hydrochloride (10 mg/1)TabletOralPoly Pharmaceuticals2011-09-15Not applicableUs
Alahist CFDexbrompheniramine maleate (2 g/1) + Dextromethorphan hydrobromide (20 g/1) + Phenylephrine hydrochloride (10 g/1)TabletOralPoly Pharmaceuticals2017-09-14Not applicableUs
Alahistdm DMDexbrompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)LiquidOralPoly Pharmaceuticals2016-09-01Not applicableUs
Bio-cnexDexbrompheniramine maleate (1 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL)LiquidOralAdvanced Generic Corporation2017-01-01Not applicableUs
BiogesicDexbrompheniramine maleate (1 mg/1) + Acetaminophen (500 mg/1)TabletOralAdvanced Generic Corporation2017-01-01Not applicableUs
Bionatuss DXPDexbrompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide (20 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL)LiquidOralAdvanced Generic Corporation2009-10-01Not applicableUs
Chlo HistDexbrompheniramine maleate (1 mg/5mL) + Chlophedianol hydrochloride (12.5 mg/5mL)LiquidOralR. A. Mc Neil Company2014-09-15Not applicableUs
International/Other Brands
Disophrol (Schering) / Drixoral (Schering )
Categories
UNII
75T64B71RP
CAS number
132-21-8
Weight
Average: 319.239
Monoisotopic: 318.073161265
Chemical Formula
C16H19BrN2
InChI Key
ZDIGNSYAACHWNL-HNNXBMFYSA-N
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
IUPAC Name
[(3S)-3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1

Pharmacology

Indication

For treatment and relief of symptoms of allergies, hay fever, and colds

Associated Conditions
Pharmacodynamics

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexbrompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Mechanism of action

Dexbrompheniramine competitively binds to the histamine H1-receptor. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Antihistamines are well absorbed from the gastrointestinal tract after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic (cytochrome P-450 system), some renal.

Route of elimination
Not Available
Half life

25 hours

Clearance
Not Available
Toxicity

Signs of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Dexbrompheniramine H1-Antihistamine ActionDrug action
Dexbrompheniramine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbexinostatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Abexinostat.Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acetylglycinamide chloral hydrate.Experimental
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Dexbrompheniramine.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alaproclate.Experimental
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Dexbrompheniramine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dexbrompheniramine.Approved, Illicit
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dexbrompheniramine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alverine.Approved, Investigational
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Dexbrompheniramine.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amifampridine.Approved
AmikacinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dexbrompheniramine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved, Illicit, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Anagrelide.Approved
AniracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aniracetam.Experimental
AntazolineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Antazoline.Approved
APD791The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Arbekacin.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Dexbrompheniramine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aripiprazole lauroxil.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Dexbrompheniramine.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Azaperone.Investigational, Vet Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Dexbrompheniramine.Approved
AZD-3043The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with AZD-3043.Investigational
AzelastineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dexbrompheniramine.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Beclamide.Experimental
BedaquilineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Bedaquiline.Approved
BekanamycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dexbrompheniramine.Approved
BenzoctamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benzoctamine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineDexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Besifloxacin.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dexbrompheniramine.Approved, Investigational
BifemelaneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bifeprunox.Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Dexbrompheniramine.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Blonanserin.Approved, Investigational
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dexbrompheniramine.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brotizolam.Approved, Investigational, Withdrawn
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Dexbrompheniramine.Approved
BufotenineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bufotenine.Experimental, Illicit
BuprenorphineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bupropion.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Dexbrompheniramine.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dexbrompheniramine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Captodiame.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Carbinoxamine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Caroxazone.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cathinone.Illicit
CeritinibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dexbrompheniramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Dexbrompheniramine.Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexbrompheniramine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine.Approved
CilansetronThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cilansetron.Investigational
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Dexbrompheniramine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cinitapride.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cinnarizine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cinolazepam.Approved
CinoxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cisatracurium.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dexbrompheniramine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clozapine.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Colistin.Approved
CrizotinibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Dexbrompheniramine.Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Dexbrompheniramine.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine.Investigational
DasatinibThe risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dexbrompheniramine.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Decamethonium.Approved
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Dexbrompheniramine.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Delamanid.Approved, Investigational
DelorazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Deutetrabenazine.Approved, Investigational
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dexchlorpheniramine maleate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextofisopam.Investigational
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dexbrompheniramine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Difenoxin.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Dexbrompheniramine.Vet Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dixyrazine.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Domoic Acid.Experimental
DomperidoneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dyclonine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ebastine.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Edivoxetine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eletriptan.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eltoprazine.Investigational
EmedastineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Emedastine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Enflurane.Approved, Investigational, Vet Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Dexbrompheniramine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Entinostat.Investigational
EperisoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergotamine.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Dexbrompheniramine.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dexbrompheniramine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethadione.Experimental
EthanolDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fabomotizole.Experimental
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexbrompheniramine.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Dexbrompheniramine.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Dexbrompheniramine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluanisone.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Dexbrompheniramine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fludiazepam.Approved, Illicit
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Dexbrompheniramine.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Dexbrompheniramine.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dexbrompheniramine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gaboxadol.Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Dexbrompheniramine.Approved
GallamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dexbrompheniramine.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gantacurium Chloride.Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Dexbrompheniramine.Approved, Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gedocarnil.Experimental
GemifloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with GENTAMICIN C1A.Experimental
GepefrineGepefrine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gepirone.Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Dexbrompheniramine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Glutethimide.Approved, Illicit
GoserelinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Goserelin.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexobarbital.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Dexbrompheniramine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hydracarbazine.Experimental
HydrocodoneDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Dexbrompheniramine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hypericin.Investigational
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexbrompheniramine.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ibutilide.Approved
IdalopirdineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imagabalin.Investigational
ImatinibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Imatinib.Approved
ImipramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Imipramine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine oxide.Experimental
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dexbrompheniramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Dexbrompheniramine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iproniazid.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dexbrompheniramine.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Dexbrompheniramine.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Dexbrompheniramine.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ivosidenib.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Dexbrompheniramine.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ketotifen.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lanicemine.Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Dexbrompheniramine.Approved, Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lasmiditan.Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lithium cation.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lomefloxacin.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lormetazepam.Approved
LorpiprazoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lortalamine.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lumateperone.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with m-Chlorophenylpiperazine.Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Macimorelin.Approved, Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medifoxamine.Experimental
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Dexbrompheniramine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative and stimulatory activities of Dexbrompheniramine.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mephenoxalone.Experimental
MephentermineMephentermine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mepyramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Dexbrompheniramine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine.Approved
MethotrimeprazineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methysergide.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dexbrompheniramine.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metocurine Iodide.Approved, Withdrawn
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Dexbrompheniramine.Approved
MetyrosineDexbrompheniramine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mianserin.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental, Illicit, Investigational
MifepristoneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Dexbrompheniramine.Approved
MirtazapineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with MK-212.Investigational
MMDAMMDA may decrease the sedative and stimulatory activities of Dexbrompheniramine.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mocetinostat.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Moclobemide.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Dexbrompheniramine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mosapride.Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Moxifloxacin.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nalidixic Acid.Approved, Investigational
NaluzotanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefiracetam.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Dexbrompheniramine.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nemonoxacin.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Niaprazine.Experimental
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Dexbrompheniramine.Approved, Investigational
NilotinibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dexbrompheniramine.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nordazepam.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Dexbrompheniramine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Octamoxin.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexbrompheniramine.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dexbrompheniramine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Opium.Approved, Illicit
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Dexbrompheniramine.Vet Approved
OrphenadrineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Osanetant.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxaflozane.Experimental
OxaliplatinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxaliplatin.Approved, Investigational
OxaprotilineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxaprotiline.Experimental
OxatomideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxatomide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Dexbrompheniramine.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexbrompheniramine.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pancuronium.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Papaverine.Approved, Investigational
ParaldehydeDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dexbrompheniramine.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Dexbrompheniramine.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Dexbrompheniramine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Penimepicycline.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perazine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pheniprazine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pheniramine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phensuximide.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dexbrompheniramine.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipecuronium.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Dexbrompheniramine.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pirlindole.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Dexbrompheniramine.Experimental
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Dexbrompheniramine.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Dexbrompheniramine.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pracinostat.Investigational
PramipexoleDexbrompheniramine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pridinol.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Primidone.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propanidid.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propiopromazine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Proxibarbal.Experimental
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Dexbrompheniramine.Investigational
PRX-08066The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with PRX-08066.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramosetron.Approved, Investigational
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Dexbrompheniramine.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ribociclib.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ribostamycin.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ricolinostat.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Dexbrompheniramine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Riluzole.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Dexbrompheniramine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Dexbrompheniramine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rizatriptan.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rolitetracycline.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Romidepsin.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Romifidine.Vet Approved
RopiniroleDexbrompheniramine may increase the sedative activities of Ropinirole.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Dexbrompheniramine.Approved, Investigational
RotigotineDexbrompheniramine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Roxithromycin.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dexbrompheniramine.Approved
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Dexbrompheniramine.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Rupatadine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dexbrompheniramine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dexbrompheniramine.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Dexbrompheniramine.Vet Approved, Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Selegiline.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sisomicin.Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sitafloxacin.Experimental, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Dexbrompheniramine.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Dexbrompheniramine.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sparfloxacin.Approved, Investigational
St. John's WortThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Dexbrompheniramine.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Dexbrompheniramine.Approved, Investigational
SuvorexantDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Talopram.Experimental
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Dexbrompheniramine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tandospirone.Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Dexbrompheniramine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with TD-8954.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Technetium Tc-99m ciprofloxacin.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tegaserod.Approved, Investigational, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine.Approved, Investigational
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dexbrompheniramine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrodotoxin.Investigational
ThalidomideDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tolperisone.Approved, Investigational
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Dexbrompheniramine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Dexbrompheniramine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimethadione.Approved
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Dexbrompheniramine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dexbrompheniramine.Approved, Vet Approved
TropisetronThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tropisetron.Approved, Investigational
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tucidinostat.Investigational
UrapidilThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vancomycin.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Dexbrompheniramine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Dexbrompheniramine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinylbital.Experimental
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Dexbrompheniramine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dexbrompheniramine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zolmitriptan.Approved, Investigational
ZolpidemDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dexbrompheniramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Walter, L.A.; U.S. Patents 3,061,517; October 30, 1962; and 3,030,371; April 17, 1962; both assigned to Schering Corporation.

General References
Not Available
External Links
Human Metabolome Database
HMDB0014549
PubChem Compound
16960
PubChem Substance
46505186
ChemSpider
16068
ChEBI
59269
ChEMBL
CHEMBL1201287
Therapeutic Targets Database
DAP001068
PharmGKB
PA164746251
Wikipedia
Dexbrompheniramine
ATC Codes
R06AB56 — Dexbrompheniramine, combinationsR06AB06 — Dexbrompheniramine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
Packagers
  • Poly Pharmaceuticals Inc.
Dosage forms
FormRouteStrength
TabletOral2 mg/1
TabletOral
Tablet, extended releaseOral
Tablet; tablet, extended releaseOral
LiquidOral
SyrupOral2 mg/5mL
Tablet, chewableOral1 mg/1
SyrupOral
Prices
Unit descriptionCostUnit
Ala-hist ir 2 mg tablet0.82USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)113-115US. Patent 3,030,371.
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP3.63ALOGPS
logP3.75ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)9.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity83.67 m3·mol-1ChemAxon
Polarizability31.84 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9648
Blood Brain Barrier+0.9576
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.6242
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.93
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateSubstrate0.8346
CYP450 3A4 substrateSubstrate0.5898
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8398
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.9351
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0758 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9121
hERG inhibition (predictor II)Inhibitor0.7207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0292-0940000000-f369442eba5344b3ecb4

Taxonomy

Description
This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pheniramines
Direct Parent
Pheniramines
Alternative Parents
Bromobenzenes / Aralkylamines / Aryl bromides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organobromides / Hydrocarbon derivatives
Substituents
Pheniramine / Bromobenzene / Halobenzene / Aralkylamine / Aryl bromide / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
brompheniramine (CHEBI:59269)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. McLeod RL, Mingo G, O'Reilly S, Ruck LA, Bolser DC, Hey JA: Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology. 1998 Aug;57(2):57-64. [PubMed:9691225]
  2. Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56. [PubMed:1680053]
  3. Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23. [PubMed:1970615]
  4. Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410]
  5. Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH: Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Exp Lung Res. 2008 Dec;34(10):681-93. doi: 10.1080/01902140802339623. [PubMed:19085565]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:53